Tumor inflamatorio miofibroblástico peritoneal. Respuesta favorable asociada a infliximab: Caso clínico

Grünholz, Daniela; Appiani, Franco; Abarca, Constanza; Manríquez, María; Pinilla, Jorge; Wainstein, Eduardo.
Rev. méd. Chile ; 143(7): 943-947, jul. 2015. ilus
Artículo en Español | LILACS | ID: lil-757919

Documentos relacionados

  1. [Peritoneal myofibroblastic tumor successfully treated with infliximab: Report of one case].
  2. PIPAC for the Treatment of Gynecologic and Gastrointestinal Peritoneal Metastases: Technical and Logistic Considerations of a Phase 1 Trial.
  3. Organoids derived from patients provide a new opportunity for research and individualized treatment of malignant peritoneal mesothelioma.
  4. Efficacy of AS versus SOX regimen as first-line chemotherapy for gastric cancer patients with peritoneal metastasis: a real-world study.
  5. Metal-enriched HSP90 nanoinhibitor overcomes heat resistance in hyperthermic intraperitoneal chemotherapy used for peritoneal metastases.
  6. Hyperthermic pressurized intraperitoneal aerosol drug delivery system in a large animal model: a feasibility and safety study.
  7. Safety and Feasibility of High-Pressure/High-Dose Pressurized Intraperitoneal Aerosol Chemotherapy (HP/HD-PIPAC) for Primary and Metastatic Peritoneal Surface Malignancies.
  8. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal malignancy: initial experience of the first program in the Baltic countries.
  9. HIPEC Methodology and Regimens: The Need for an Expert Consensus.
  10. High intra-abdominal pressure during hyperthermic intraperitoneal chemotherapy (HIPEC) following cytoreductive surgery (CRS) for peritoneal surface malignancies.